✨ Free AI Report
Oryzon Genomics S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Oryzon Genomics S.A.
Company Research

Oryzon Genomics S.A.: Business Overview, Financials & Competitive Analysis

Oryzon Genomics is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches for di...

Analyst-debate audio for Oryzon Genomics S.A.

AskCyborg analysts argue the bull and bear cases for Oryzon Genomics S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Differentiated epigenetics platform with solid IP position, but pre-commercial stage requires successful clinical validation and...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Epigenetics / Clinical Stage Development
1 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Oryzon Genomics S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Oryzon Genomics S.A. Overview

Pro stress-test →

Oryzon Genomics is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches for disorders of the central nervous system (CNS), as well as oncology and hematology. The company leverages proprietary epigenetic platforms to discover and develop innovative therapeutics targeting unmet medical needs.

Strategic Profile

Pro stress-test →

The company develops proprietary drug candidates through clinical Phase II, at which point it decides on a case-by-case basis to either keep development in-house or partner or out-license the compound for late stage development and commercialization. The company has a strong intellectual property position and originates and owns all its IP portfolio, created internally through a concerted effort of its functional genomics, medicinal chemistry, preclinical and clinical development teams.

Competitive Landscape

Pro stress-test →

Oryzon competes within the broader epigenetics drug development space against other biotech companies focused on histone deacetylase inhibitors and lysine-specific demethylase inhibitors. Roche previously had rights to ORY-1001 but discontinued development and returned rights to Oryzon Genomics. The company's strength lies in its originator position and full IP ownership rather than competing on size or resources.

Industry Context

Oryzon Genomics S.A. operates in Biopharmaceuticals - Epigenetics / Clinical Stage Development.

Key facts

Founded: 2003 · Headquarters: Barcelona, Spain

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Oryzon Genomics S.A..

  • Leading European player in epigenetics-based drug development with internally-created IP portfolio across CNS, oncology, and hematology
  • Phase II pipeline includes iadademstat (LSD1 inhibitor) for oncology and vafidemstat (CNS-optimized LSD1 inhibitor) for neurological disorders
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Celebrated 10th anniversary since listing on Spanish Stock Exchange
  • March 2026Analyst price target of 7.067 EUR with 3 buy recommendations and +122% upside potential noted
Get alerted when Oryzon Genomics S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

HDAC inhibitors/LSD1 inhibitorsCompeting epigenetics-based therapeutic approaches in oncology and CNS→

Compare Oryzon Genomics S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Oryzon Genomics S.A. operates in Biopharmaceuticals - Epigenetics / Clinical Stage Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Epigenetics / Clinical Stage Development research →
NEW · MCP server

Ask your AI assistant about Oryzon Genomics S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Oryzon Genomics S.A. and its top competitor on Cyborg Score”
“What did Oryzon Genomics S.A. do this quarter?”
“Is Oryzon Genomics S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Oryzon Genomics S.A. do?+
Oryzon Genomics is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches for di...
What is Oryzon Genomics S.A.'s Cyborg Score?+
Oryzon Genomics S.A. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Oryzon Genomics S.A.'s main competitors?+
Named competitors include HDAC inhibitors/LSD1 inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Oryzon Genomics S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Oryzon Genomics S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Oryzon Genomics S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.